NASDAQ:GRCE Grace Therapeutics (GRCE) Stock Price, News & Analysis $2.33 -0.03 (-1.27%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$2.33 +0.00 (+0.17%) As of 05/5/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Grace Therapeutics Stock (NASDAQ:GRCE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Grace Therapeutics alerts:Sign Up Key Stats Today's Range$2.27▼$2.3850-Day Range$2.10▼$5.1352-Week Range$1.79▼$5.18Volume297,327 shsAverage Volume1.42 million shsMarket Capitalization$36.05 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Grace Therapeutics, Inc. (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease. The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways. Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.AI Generated. May Contain Errors. Read More Grace Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreGRCE MarketRank™: Grace Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 615th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingGrace Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialGrace Therapeutics has a consensus price target of $6.00, representing about 157.5% upside from its current price of $2.33.Amount of Analyst CoverageGrace Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Grace Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Grace Therapeutics are expected to grow in the coming year, from ($0.95) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Grace Therapeutics is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Grace Therapeutics is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGrace Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Grace Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.17% of the float of Grace Therapeutics has been sold short.Short Interest Ratio / Days to CoverGrace Therapeutics has a short interest ratio ("days to cover") of 1.53, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Grace Therapeutics has recently increased by 17.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGrace Therapeutics does not currently pay a dividend.Dividend GrowthGrace Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest21 people have searched for GRCE on MarketBeat in the last 30 days. This is an increase of 950% compared to the previous 30 days.MarketBeat Follows11 people have added Grace Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Grace Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.10% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions6.08% of the stock of Grace Therapeutics is held by institutions.Read more about Grace Therapeutics' insider trading history. Receive GRCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Grace Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRCE Stock News HeadlinesGrace Therapeutics (GRCE) price target decreased by 47.83% to 6.12April 28, 2026 | msn.comFDA declines Grace's stroke drug over manufacturing and packaging issues, shares slumpApril 25, 2026 | msn.comWhere the SpaceX "Tidal Wave" hits firstThe SpaceX and xAI IPO could trigger one of the largest capital shifts in market history — $1.75 trillion moving at once. When that happens, it doesn't move evenly. Analyst Dylan Jovine has identified a critical hardware supplier tied to the infrastructure Musk is scaling in Memphis. When the S-1 goes public in June, this dependency becomes impossible to ignore. | Behind the Markets (Ad)Grace Therapeutics Shares Fall After FDA Flags Issues in Aneurysm Treatment ApplicationApril 23, 2026 | marketwatch.comFDA declines Grace's stroke drug over manufacturing and packaging issuesApril 23, 2026 | msn.comUS FDA declines to approve Grace Therapeutics' drug for a type of strokeApril 23, 2026 | reuters.comGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104April 23, 2026 | globenewswire.comGRCE stock in spotlight ahead of FDA verdict on brain bleed drug this weekApril 22, 2026 | msn.comSee More Headlines GRCE Stock Analysis - Frequently Asked Questions How have GRCE shares performed this year? Grace Therapeutics' stock was trading at $3.46 at the beginning of 2026. Since then, GRCE shares have decreased by 32.7% and is now trading at $2.33. How were Grace Therapeutics' earnings last quarter? Grace Therapeutics, Inc. (NASDAQ:GRCE) posted its earnings results on Thursday, February, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.05. Who are Grace Therapeutics' major shareholders? Top institutional shareholders of Grace Therapeutics include Kestra Private Wealth Services LLC (0.08%). How do I buy shares of Grace Therapeutics? Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/12/2026Today5/05/2026Next Earnings (Estimated)6/22/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 13 days, GRCE's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRCE Previous SymbolNASDAQ:GRCE CIK1444192 Webwww.acastipharma.com Phone818-839-4378Fax45-0687-2272EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Grace Therapeutics$6.00 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+157.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.57 million Net MarginsN/A Pretax MarginN/A Return on Equity-15.58% Return on Assets-14.51% Debt Debt-to-Equity RatioN/A Current Ratio14.96 Quick Ratio14.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book0.48Miscellaneous Outstanding Shares15,470,000Free Float13,756,000Market Cap$36.05 million OptionableN/A Beta0.32 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:GRCE) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredHow to collect $1,170/month from silverThere is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...Investors Alley | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredDid you miss The Dark AI Summit?Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...Brownstone Research | SponsoredIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextJim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...Paradigm Press | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
